论文部分内容阅读
目的:分析和研究针对高血压合并高脂血症患者给予辛伐他汀和缬沙坦治疗后的临床疗效。方法:选取2014年10月~2015年12月来我院治疗的高血压合并高脂血症患者126例作为研究对象,均分成两组,每组各63例。对照组采用阿托伐他汀和氨氯地平进行治疗,而试验组给予辛伐他汀和缬沙坦干预治疗。结果 :结果显示,试验组患者在治疗后出现恶心呕吐、头痛头晕、四肢无力等不良状况人数均少于对照组患者,存在差别,P<0.05。两组患者的血脂改善状况可知,试验组患者在治疗后甘油三酯、总胆固醇、高低密度脂蛋白等临床指标均优于对照组,差别存在,P<0.05。结论 :针对高血压伴高脂血症患者给予辛伐他汀和缬沙坦在治疗上有一定的作用价值,可以明显的改善患者治疗期间的各项指标,减少不良状况的发生。
Objective: To analyze and study the clinical effects of simvastatin and valsartan in patients with hypertension and hyperlipidemia. Methods: A total of 126 hypertensive patients with hyperlipidemia who were treated in our hospital from October 2014 to December 2015 were selected and divided into two groups (63 in each group). The control group was treated with atorvastatin and amlodipine, while the experimental group was treated with simvastatin and valsartan. Results: The results showed that there were differences between the two groups in the incidence of nausea and vomiting, headache and dizziness, weakness of extremities and other adverse events in the test group after treatment, with a difference of P <0.05. The improvement of blood lipid in both groups shows that the clinical indexes of triglyceride, total cholesterol and high and low density lipoprotein in the experimental group are better than the control group after treatment, with the difference being significant (P <0.05). Conclusion: Simvastatin and valsartan given to patients with hypertension and hyperlipidemia may have some therapeutic value. It can significantly improve the indicators of patients during treatment and reduce the incidence of adverse events.